The American Gastroenterological Association (AGA) has issued a consensus statement on the safe and efficacious use of nonsteroidal anti-inflammatory drugs (NSAIDs), including nonselective, nonsteroidal anti-inflammatory drugs (nsNSAIDs), cyclooxygenase-2 enzyme inhibitors (coxibs), and aspirin (ASA).
The American Gastroenterological Association (AGA) has issued a consensus statement on the safe and efficacious use of nonsteroidal anti-inflammatory drugs (NSAIDs), including nonselective, nonsteroidal anti-inflammatory drugs (nsNSAIDs), cyclooxygenase-2 enzyme inhibitors (coxibs), and aspirin (ASA).
The consensus statement, published in Clinical Gastroenterology and Hepatology, is based on recommendations from a multidisciplinary panel of gastroenterologists, rheumatologists, cardiologists, and internists assembled by the AGA.
The authors stressed the need for prescribers to carefully consider both the potential benefits of NSAID use and the risks of gastrointestinal (GI) and/or cardiovascular (CV) toxicity prior to prescribing specific agents or regimens.
The recommendations include: using NSAIDs with lower GI risk (including some nsNSAIDs such as ibuprofen, etodolac, and diclofenac) and coxibs for patients in whom the estimated risk of life-threatening GI complications outweighs the risk of CV events; avoiding coxibs for patients at greater risk of CV events; using low-dose ASA for patients with known CV disease or at high CV risk; limiting dosage and duration of NSAID use and avoiding combination NSAID therapy for all patients, regardless of GI and CV risks; and modifying patient risk factors for GI (through eradicating Heliobacter pylori and considering adding ≥600 mg/d misoprostil or a proton pump inhibitor in patients with a high GI risk) and CV complications (encouraging tobacco cessation and tight control of blood pressure, cholesterol, and diabetes) for all patients.
The panel noted that the concurrent use of ASA with nsNSAIDs might interfere with ASA's CV-protective effects, that ASA may decrease or eliminate the GI benefits of coxib therapy, and that current data do not support the use of buffered or coated ASA to decrease GI toxicity.
The authors stressed the need for additional data from randomized controlled trials "to clarify the relative risks and benefits of nsNSAIDs and coxibs for individual patients."
SOURCE American Gastroenterological Association; Wilcox CM, Allison J, Benzuly K, et al. Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin. Clin Gastroenterol and Hepatol. 2006;4:1082–1089.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.